BTIG Rates Tempus AI (TEM) Buy, $80 Price Target
Key Points
- BTIG kept its price target on Tempus AI at $80.00, matching its previous target.
- BTIG's $80 price target implies 18.32% upside from Tempus AI, Inc.'s ($TEM) current $67.61 share price.
- As of October 26, 2026, Tempus AI shares traded at $67.61, which is about equal to the closing price of $67.61 on October 23.
- Tempus AI has a market cap of about $12.32 billion and is expected to report earnings on November 2, 2026.
Get Tempus AI text alerts
We text you when insiders, Congress, analysts or big funds move on $TEM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tempus AI, Inc. alert may contain errors. Disclosures
On October 26, 2026, BTIG reiterated its Buy rating on Tempus AI, Inc. (TEM) with a price target of $80.00. This target remains unchanged from their previous assessment, signaling BTIG's confidence in the stock's potential.
TEM
Tempus AI, Inc.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Tempus AI, Inc.
ARK Investment Management, LLC increased its holdings in Tempus AI by 415,048 shares, bringing its total to 10,022,634 shares worth about $677.7 million. Meanwhile, Baillie Gifford & Co. trimmed its position by 459,284 shares, ending with 8,190,133 shares valued at approximately $553.8 million. Softbank Group Corporation maintained its stake at 5,405,406 shares, valued at about $365.5 million. Sumitomo Mitsui Trust Group, Inc. decreased its holdings by 237,070 shares, with a total of 4,089,029 shares worth around $276.5 million. Amova Asset Management Americas Inc also cut its stake by 237,070 shares, holding 4,089,029 shares valued at approximately $276.5 million.
Tempus AI, Inc. Stock Up 6.0%
Tempus AI shares closed at $67.61 on October 23, 2026, and were recently trading at the same level. This price is about 27.6% below the 52-week high of $93.38, yet it’s significantly above the 52-week low of $40.77, reflecting a strong recovery from earlier lows. The stock is currently trading below its 50-day moving average of $68.99 but above its 200-day average of $56.81.
$TEM price target
Tempus AI, Inc. daily closes and this analyst's $80 target. Not advice.
Recent Earnings
Tempus AI reported trailing twelve-month revenue of approximately $1.43 billion, showing a year-over-year revenue growth of 21.6%. However, the company has faced challenges, with a net margin of -17.8% and a return on equity of -67.4%. The next earnings report is scheduled for November 2, 2026, which should provide further insights into the company's performance.
Insider Buying and Selling at Tempus AI, Inc.
Several insiders sold shares of Tempus AI recently. Ryan Fukushima, an officer, sold 30,846 shares valued at about $1.93 million on September 1, 2026. Director David R Epstein sold 250 shares at an average price of $65.55, totaling $16,388 on the same day. CEO Eric Paul Lefkofsky sold 250,000 shares, amounting to approximately $19.37 million on September 22, 2026. Additionally, officer Thomas Edward Schoenherr sold 10,281 shares at an average price of $85.00, totaling $873,885 on September 25, 2026.
Analysts Set New Price Targets
On October 12, 2026, Canaccord Genuity maintained its Buy rating on Tempus AI, raising its price target from $80.00 to $95.00. JP Morgan also maintained a Neutral rating with a target increase from $45.00 to $70.00 on October 14, 2026. Needham reiterated its Buy rating on October 23, keeping the price target steady at $75.00. On the same day as BTIG's announcement, HC Wainwright & Co. maintained its Buy rating and raised the target from $66.00 to $68.00.
About Tempus AI, Inc.
Tempus AI, Inc. is a healthcare technology company based in Chicago, IL. The firm provides a platform that integrates clinical data with laboratory diagnostics and analytics, helping healthcare providers in making informed decisions. As the company continues to evolve, analysts are closely watching its performance and market position.
Bottom Line
Investors should keep an eye on Tempus AI's upcoming earnings report on November 2, 2026, for further insights into its financial health. With BTIG affirming its Buy rating and maintaining the price target at $80.00, the stock remains a focal point for analysts and investors alike.
Related Filing Alerts
Source: BTIG's rating change on $TEM (Oct 26, 2026). Written by software, not financial advice. How we make alerts